Amgen stock holds near 52-week high as guidance and dividend support outlook

Amgen (ISIN US0311621009) stock is trading close to a fresh 52-week high in late August 2026 after the biotechnology group delivered strong second-quarter 2026 results and raised its full-year earnings guidance.

Per recent market data as of August 21, 2026, Amgen shares touched a new 52-week high of $440.51 before closing the session at $439.33, leaving the stock up 34.2% year to date and well ahead of its sector and benchmark index.

Stock hovers just below record levels

Recent price history shows Amgen stock closing at $439.33 on August 21, 2026, after trading between a session low of $429.38 and the 52-week high of $440.51 on the same day. The move left the stock 1.29% higher for that session, underlining firm demand around current levels.

Year to date, Amgen shares have advanced 34.2%, compared with a 18.2% gain for a broad industry basket and a lower increase for the S&P 500 index over the same period, highlighting how investors have rewarded the company’s earnings momentum and guidance upgrades.

Second-quarter earnings beat and guidance raised

In its latest reported quarter, covering the second quarter of 2026, Amgen posted earnings per share of $6.29, surpassing the consensus estimate of $5.62 by $0.67 and improving from $6.02 in the same quarter a year earlier. This means EPS rose by 4.5% year over year while beating market expectations by almost 12% in absolute dollar terms.

Revenue performance was also robust in the second quarter of 2026, with sales reaching $10.05 billion versus analyst expectations of $9.43 billion, representing 9.5% year-over-year growth and a beat of $0.62 billion against consensus estimates. The company reported a net margin of 22.95% and a return on equity of 124.14% for the quarter, underscoring a highly profitable and capital-efficient business model.

On the back of these results, management issued fiscal 2026 earnings guidance in a range of $22.30 to $23.50 per share. The midpoint of $22.90 implies solid full-year growth compared with current-year analyst expectations of $22.92 per share, suggesting that internal guidance and external consensus are now closely aligned.

Dividend yield and analyst consensus

Alongside earnings, Amgen continues to back its shareholder-return story with a generous cash distribution. The company has declared a quarterly dividend of $2.52 per share, which translates to an annualized payout of $10.08 and a dividend yield of 2.3% based on recent trading prices around the $439 level.

Analysts tracking the stock currently expect Amgen to deliver earnings of 22.92 per share for the current fiscal year, close to the midpoint of the company’s own guidance range of $22.30 to $23.50. The average published price target stands at $380.43, which is below the recent spot price of $439.33, indicating that the stock is trading at a premium to the mean analyst objective even as the consensus rating remains at Hold.

For investors, the key numbers stand out: revenue up 9.5% year over year to $10.05 billion in the second quarter of 2026, EPS up from $6.02 to $6.29, and a year-to-date share price gain of 34.2% versus 18.2% for the broader industry. The combination of double-digit top-line growth, earnings beats and a covered dividend yield gives Amgen a balanced mix of income and growth characteristics.

Pipeline and oncology franchise underpin growth

Amgen’s growth profile is anchored in a broad biotechnology portfolio that spans oncology, bone health, cardiovascular disease and immunology. The company generates significant revenue from biologic therapies and continues to invest heavily in late-stage clinical programs targeting cancer, inflammatory diseases and rare conditions.

In oncology, Amgen markets several injectable and infusion therapies designed to manage neutropenia and support chemotherapy regimens, while also advancing next-generation biologics that target specific immune pathways. This therapeutic footprint gives the group recurring revenue streams from chronic and supportive-care products and positions it for incremental growth as new indications and line extensions are approved.

Biotech sector backdrop and competitive positioning

The broader biotechnology sector has seen renewed investor interest in 2026 as large-cap names with diversified pipelines and established cash flows stand out in a market that is differentiating sharply between profitable and pre-revenue companies. Amgen’s combination of strong free cash flow, disciplined capital allocation and a clear dividend policy supports its standing among defensive growth names in healthcare.

Compared with peers in the large-cap biotech space, Amgen’s 34.2% year-to-date share price advance places it near the upper end of performance tables, while its 2.3% dividend yield provides a higher cash return than many pure growth competitors. The trade-off is that the stock’s valuation, implied by a share price of $439.33 against guidance midpoints in the low-$20 EPS range, embeds a notable premium to some peers, which is reflected in the consensus price target of $380.43.

Flagship biologic therapies

One representative product within Amgen’s portfolio is its pegfilgrastim-based therapy used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy. The drug, delivered via prefilled syringe or on-body injector, has become a standard of care in many oncology treatment protocols and generates significant recurring revenue for the company.

Amgen has supplemented this core biologic with a range of follow-on products and combination regimens, aiming to extend the lifecycle of its proprietary technologies while defending against biosimilar competition. The company also pursues partnerships and licensing agreements to broaden access and distribution for its key therapies, reflecting a strategy that blends in-house innovation with external collaboration.

Amgen stock remains supported by earnings and dividends

Amgen trades on the Nasdaq under the ticker AMGN, and recent market data show the stock closing at $439.33 on August 21, 2026, after setting a 52-week high of $440.51 during that session. The company’s market capitalization now sits in the large-cap tier, supported by double-digit revenue growth in the latest reported quarter and a stable dividend payout policy.

For now, the combination of a strong second-quarter 2026 earnings beat, full-year EPS guidance between $22.30 and $23.50, and an annualized dividend of $10.08 per share helps to underpin Amgen stock around current levels, even as the consensus price target of $380.43 trails the actual share price.